MG63, U2OS 골육종 세포주에서 세포 증식 및 유사분열 물질 활성화 단백 활성효소 작용기전에 대한 아드레노메듈린의 효과 김정렬ㆍ최병완ㆍ박종혁ㆍ김규형 전북대학교 의학전문대학원 정형외과학교실, 임상의학연구소
INTRODUCTION
Adrenomedullin (AM) is a 52-amino-acid peptide that is formed from the proteolytic cleavage of pro AM. AM belongs to the calcitonin superfamily on account of its structural similarity to the calcitonin gene-related peptide (CGRP) and amylin 4) . Since its isolation from an adrenal tumor (pheochromocytoma) in 1993, AM has been shown to be present in many mammalian tissues and fluids, regulating a variety of physiological activities in normal and malignant settings 3) . The pleiotopic activities of AM were recognized within a few years of its initial characterization as a vasodilatory peptide 3, 4) .
The expression and secretion of AM has been demonstrated in many tumors and biological fluids and has been suggested to modulate a variety of physiological processes 3) . AM expression is stimulated by cytokines and hypoxia and its promoter contains several putative hypoxia response elements 16) . Hypoxia induces AM expression and secretion in many cell types including carcinoma cell lines and endothelial cells 10) . Moreover, hypoxia is a common feature of the microenvironment in solid tumors and is one of the driving forces for cancer growth and progression. AM has been suggested to play a role as a promoter of these processes 2) . AM promotes the formation of tumors by stimulating the autocrine growth and survival of tumor cells, as well as through its paracrine effects on the surrounding vessels. The possible intracellular mechanisms underlying the effects of AM suggest its potential role in tumor progression.
AM signal transduction differs according to the cell types and involves several pathways 3, 11) . Increasing evidence suggests that the activation or disruption of AM signaling may contribute to various pathologies, such as, ischemia-induced damage and neoplastic growth.
Cell growth, division, differentiation and deaths are now known to be regulated in part by the mitogen activated protein kinase (MAPK) pathway 9, 14) . Cellular signal transduction is a two step-process: a signaling molecule is sensed by a receptor on the target cell and the receptor is then activated. The response is amplified when the receptor sensing the signal is a catalyst, a kinase for example. At least three parallel MAPK pathways have been identified, extracellular signal regulated kinase (ERK), stress activated protein kinase (SAPK), also known as JNK for c-jun-N-terminal kinase), and the p38/MAPK pathways.
It is becoming increasingly evident that AM plays a role in tumor proliferation. Therefore, this study examined the cell proliferation stimulated by AM as well as the the signaling pathways responsible for the activations of ERK 1 and 2 by AM in human osteosarcoma was warranted.
MATERIALS AND METHODS

Cell culture
The human osteosarcoma (OS) cell lines MG 63 and U2OS (Korean Cell Line Bank, Seoul, Korea) were cultured. All experiments were carried out in Eagle's modified minimal essential medium containing 10% inactivated fetal bovine serum (GIBCO, Carlsbad, CA). In all the experiments, the OS cells were cultured in 10% serum and harvested with trypsin which was blocked by complete media as soon as the cells had become detached. Trypan blue exclusion was used to test for the cell viability in order to exclude the possibility that the cells had been damaged by trypsin. In all the experiments, the cells were left to recover from trypsinization for 24h before being treated. The media were replaced after the third day, only in the experiments requiring longer treatment times. In all experiments, the cells were plated at the same density, i,e., at densities equivalent to 3,000 cells/well of a 96 well plate.
Chemicals
AM (1-52) was purchased from Sigma (St. Louis, MO) and was used at concentrations of 10 nM, 50 nM, and 100 nM in both cell lines.
Cell proliferation assay by cell count
The level of cell proliferation was determined by counting the cells, as described elsewhere 1) . Briefly, the MG63 and U2OS cells (10,000 cells/ well) were plated in a 12-well tissue culture plate containing the minimum essential medium (MEM) with 10% of fetal bovine serum (FBS). Immediately after attachment to the plates, cells were switched to serum-free MEM for 24h. Subsequently, the cells were either left untreated or treated with AM (1, 10, or 100 ng/ml) in the presence or absence of PD98059 (10 uM) and incubated at 37 o C for 3 days. Subsequently, they were trypsinized and the living cells (trypan blue exclusion) were counted using a hemocytometer.
Cell proliferation measurements using an en-
zyme-derived formazan dye from the tetrazolium salt (WST-1) assay
The viabilities of the osteosarcoma cells was 
MAP kinase inhibition studies
The MG63 and U2OS cells were incubated for 30 min in the presence of 10 uM of 2'-amino-3'methoxyflavone (PD 98059; a specific MEK1 inhi- 
RESULTS
AM treatment increases cell survival in osteosarcoma cell lines
The proliferative effects of AM on the two osteosarcoma cell lines (MG63, U2OS) were assessed by cell counting. Treatment with AM for 24 h, in cultures grown in medium containing 10% inactivation. FBS induced dose-dependant increases in the numbers of cells in both cell lines ( Fig. 1 ) and significant increases were observed at AM concentrations of 50 nM or greater. The stimulations were maintained for 48 h (Fig. 2) .
The cell viability was determined using WST-1 assays. Fig. 3 shows that AM increased the cell viability in both cell lines in a dose-dependant manner up to 50 nM. AM at 50 nM increased the cell viability of MG63 and U2OS cells to ap- (Fig. 4) . The stimulation were maintained for 48 h.
Effect of PD98059 on AM-stimulated osteosarcoma cell lines
As shown in Fig. 1, 100 
AM treatment increases expression of ERK
MAP kinase
Polyclonal antibodies against the conserved,
non-phosphorylated regions in mammalian ERK1
and ERK2 MAP kinase were used to probe the immunoblots of the osteosarcoma cell lines (MG63, U2OS). Phospho-specific antibodies, which detect the active forms of the MAP kinase, were used. ERK1 and 2, MAPK were found to be activated within 3 hours after the AM treatment. A strongly immunoreactive protein of molecular weight of about 42 kDa was obtained. Treatment with AM at 100 nM caused a two-fold increase in the phosphor-MAP kinase levels without affecting the total MAPK protein levels (Fig. 6 ). Furthermore, this increase in the phosphor-MAP kinase level was prevented by a co-treatment with 100 nM AM and 10 uM ( Fig. 7) . For example, AM is expressed in brain tumors 13) and binds to a neuroblastoma cell line 15) . Martinez In conclusion, AM stimulates the activity of ERK in the two osteosarcoma cell lines examined, which is blocked by PD98059. The inhibition of ERK by PD98059 suggests that the mitogenic effect of AM is mediated in part through ERK dependant activation. Therefore, AM inhibition offers a therapeutic strategy for preventing osteosarcoma progession. However, further studies will be needed to exam the expression of AM and its distribution in human osteosarcoma tissues.
DISCUSSION
